pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

symphogen PRESS RELEASE ARCHIVE

Jun 4, 2020

Servier Completes the Acquisition of Symphogen English Français español Deutsch

Apr 3, 2020

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its RandD pipeline

Apr 3, 2020

Servier underskriver endelig aftale om at erhverve Symphogen, en førende antistof discovery virksomhed, for at styrke Serviers kapacitet inden for antistoffer samt dets forskning og udvikling

Aug 5, 2019

Symphogen Selects TransPerfect’s TI GlobalLearn Learning Management System for Study Personnel Training

May 16, 2019

Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials

May 15, 2019

Symphogen announces new capital raise and explores strategic options

Nov 7, 2018

Symphogen Selects TransPerfect's Trial Interactive eTMF Technology And Services

Nov 7, 2018

Symphogen Selects TransPerfect’s Trial Interactive eTMF Technology and Services

Sep 3, 2018

Symphogen elects new Board members to support the Company's long-term development

Jul 10, 2018

Symphogen A/S and Selexis Expand Relationship as Symphogen Advances its Monoclonal Antibody (mAb) Mixture Pipeline

Sep 11, 2017

Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Aug 31, 2017

Symphogen Presents Promising Results From a Randomized Phase 2 Study With Sym004 at ESMO 2017 Congress

Sep 14, 2016

Symphogen Names New Chief Financial Officer

Aug 18, 2016

Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director

Jun 29, 2016

Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGEs (Selexis Genetic Elements)

May 11, 2016

Symphogen Announces the Appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors

Apr 12, 2016

Symphogen Initiates Anti-MET Clinical Program and Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans

Jan 4, 2016

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

Oct 22, 2015

Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors

May 28, 2015

Symphogen’s Antibody Mixtures Highlighted in Three Peer-Reviewed Journals

Jan 29, 2015

Symphogen Regains Rights to Sym004

May 19, 2014

Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer

Jan 14, 2014

Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA

Jan 14, 2014

Symphogen Presents Corporate Progress and Outlook at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, CA

Dec 20, 2013

Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director

Dec 20, 2013

Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director

Oct 15, 2013

Symphogen and Open Monoclonal Technology Announce Collaboration

Jun 26, 2013

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration

Jun 2, 2013

Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture

May 30, 2013

Symphogen to Report New Data on Anti-EGFR Monoclonal Antibody Mixture at ASCO

May 2, 2013

Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 Million (USD 185 Million)

May 2, 2013

Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 million (USD 185 Million)

Apr 10, 2013

Symphogen Presents New pan-HER data at Annual AACR Meeting

Jan 3, 2013

Symphogen to Present at Annual J.P. Morgan Healthcare Conference

Sep 6, 2012

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

Sep 6, 2012

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA

Aug 22, 2012

Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal

Apr 2, 2012

Symphogen Names Martin Olin Chief Financial Officer and Receives 2nd Tranche From €100 Million 2011 Financing

Dec 12, 2011

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Dec 6, 2011

Symphogen to Present Rozrolimupab (SYM001) Final Data at 2011 ASH Meeting

Aug 23, 2011

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Jun 10, 2011

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association

Jun 6, 2011

Symphogen Presents Results from the First Clinical Trial with Sym004 at ASCO

Jun 2, 2011

Symphogen to Present Rozrolimupab (SYM001) Data at European Hematology Association Meeting

Apr 19, 2011

Symphogen Welcomes Four New Board Members

Apr 15, 2011

Symphogen Names New Chief Scientific/Medical and Business Officers

Mar 7, 2011

Symphogen Receives US Patent on Lead Cancer Compound Sym004

Feb 6, 2008

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody

Google Analytics Alternative